Attached files
| file | filename |
|---|---|
| S-1/A - AMENDMENT NO. 19 TO FORM S-1 - Vyant Bio, Inc. | d254016ds1a.htm |
| EX-3.2 - EX-3.2 - Vyant Bio, Inc. | d254016dex32.htm |
| EX-1.1 - EX-1.1 - Vyant Bio, Inc. | d254016dex11.htm |
| EX-3.8 - EX-3.8 - Vyant Bio, Inc. | d254016dex38.htm |
| EX-23.1 - EX-23.1 - Vyant Bio, Inc. | d254016dex231.htm |
| EX-10.70 - EX-10.70 - Vyant Bio, Inc. | d254016dex1070.htm |
| EX-10.72 - EX-10.72 - Vyant Bio, Inc. | d254016dex1072.htm |
Exhibit 10.71
March 19, 2013
NNJCA Capital, LLC
100 First Street – Suite 301
Hackensack, New Jersey 07601
Attention: Dr. Andrew Pecora
| Re: | Amended and Restated Credit Agreement with Cancer Genetics, Inc. |
Dear Dr. Pecora:
This letter agreement will memorialize your agreement with respect to that certain Amended and Restated Credit Agreement, dated as of February 13, 2012 (the “Credit Agreement”), by and among Cancer Genetics, Inc., a Delaware corporation (the “Company”), John Pappajohn, Pecora and Company and NNJCA Capital, LLC (the “Lenders”), and the Promissory Note issued pursuant to the Credit Agreement in the principal amount of $1,500,000 (the “Note”). The promises set forth in this letter agreement are made to induce us and our underwriters to proceed with the Company’s initial public offering, which is also beneficial to you.
You hereby irrevocably agree to extend the maturity date under the Credit Agreement and the Note to August 15, 2013. Other than as specifically set forth in this letter agreement, all other terms of the Credit Agreement and the Note are and will remain unchanged and in full force and effect.
| Very truly yours, | ||
| Cancer Genetics, Inc. | ||
| By: | /s/ Panna L. Sharma | |
| Panna L. Sharma | ||
| President and CEO | ||
| Agreed to and Accepted by: | ||
| NNJCA CAPITAL, LLC | ||
| By: | /s/ Andrew Pecora | |
| Name: | Andrew Pecora | |
| Title: | Manager (President) | |